Antibody molecules having specificity for human IL-6

Details Antibody molecules having specificity for human IL-6 Antibody molecules having specificity for human IL-6

2006-12-08

2011-12-13

Jiang, Dong (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S387300, C530S388100, C530S351000

Reexamination Certificate

active

08075889

ABSTRACT:
The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

REFERENCES:
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5618700 (1997-04-01), Novick et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5667425 (1997-09-01), Pineau et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5856135 (1999-01-01), Tsuchiya et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 7291721 (2007-11-01), Giles-Komar et al.
patent: 0 392 745 (1994-11-01), None
patent: 0 438 474 (1996-05-01), None
patent: 0 463 151 (1996-06-01), None
patent: 0 546 073 (1997-09-01), None
patent: 0983767 (2000-03-01), None
patent: 0 948 544 (2003-05-01), None
patent: 1 090 037 (2004-11-01), None
patent: 1536012 (2005-06-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 89/00195 (1989-01-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/02551 (1992-02-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO92/22583 (1992-12-01), None
patent: WO 92/22853 (1992-12-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 03/031581 (2003-04-01), None
patent: WO 2004/039826 (2004-05-01), None
patent: WO2004/051268 (2004-06-01), None
patent: WO2004/106377 (2004-12-01), None
patent: WO2005/003169 (2005-01-01), None
patent: WO2005/003170 (2005-01-01), None
patent: WO2005/003171 (2005-01-01), None
patent: WO2005/113605 (2005-12-01), None
patent: WO2005/117984 (2005-12-01), None
patent: WO 2006/119115 (2006-11-01), None
MacCallum et al. Antibody-antigen Interactions: Contact Analysis and Binding Site Topography. J. Mol. Biol., 1996, 262:732-745.
Padlan et al. Structure of an antibody-antigen complex: Crystal structure of the HyHEL-10 Fab-lysozyme complex. Proc. Natl. Acad. Sci. USA, 1989, 86 : 5938-5942.
Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”.
Pascalis et al. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J. Immunol. 2002, 169:3076-3084.
Adair, J.R., et al., “Therapeutic antibodies,” Drug Design Reviews—Online, 2005, 2(3), 209-217.
Akira, S., et al., Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) FASEB J., 1990, 4, 2860-2867.
Ames, R.S., et al., “Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins,” J. Immunol Methods, 1995, 184, 177-186.
Angal, S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Molecular Immunology, 1993, 30(1), 105-108.
Atreya, R., et al., “Blockade of interleukin 6transsignaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental cotitis in vivo,” Nature Amer., 2000, 6(5), 583-588.
Babcook, J., et al., “A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities,” Proc. Natl. Acad. Sci. USA, 1996, 93, 7843-7848.
Baxter, N.J., et al., Temperature dependence of1H chemical shifts in proteins, J. Biomol. NMR, 1997, 9, 359-369.
Bock, G.H., et al., “Characterization of a new IL-6-dependent human B-lymphoma cell line in long term culture,” Cytokine, 1993, 5(5), 480-489.
Boulanger, M.J., et al., “Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex,” Science, 2003, 300, 2101-2104.
Brakenhoff, J.P.J., et al., “Structure-function analysis of human IL-6; epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants,” J. of Immunology, 1990, 145(2), 561-568.
Bravo, J., et al., “New EMBO members' review: Receptor recognition by gp130 cytokines,” EMBO J., 2000, 19(11), 2399-2411.
Brinkman, U., et al., “Phage display of disulfide-stabilized Fv fragments,” J. Immunol. Methods, 1995, 182, 41-50.
Burton, D.R., et al., “Human antibodies from combinatorial libraries,” Advances in Immunology, 1994, 57, 191-280.
Chapman, A., “PEGylated antibodies and antibody fragments for improved therapy: a review,” Advanced Drug Delivery Reviews, 2002, 54, 531-545.
Chomarat, P., et al., “IL-6 switches the differentiation of monocytes from denditic cells to macrophages,” Nature Immunol., 2000, 6, 510-514.
Chothia, C., et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J. Mol. Biol., 1987, 196, 901-917.
Cole, S.P.C., et al., “The EBV-hybridoma technique and its application to human lung cancer,” Monoclonal Antibodies & Cancer Therapy, Alan R. Liss, Inc., 1985, 77-96.
Crameri, A., et al., “DNA shuffling of a family of genese from diverse species accelerates directed evolution,” Nature, 1998, 391, 288-291.
Delaglio, F., et al., “NMRPipe: a multidimensional spectral processing system based on UNIX pipes,” J. Biomol. NMR, 1995, 6, 277-293.
Dubowchik, G.M., et al., “Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs,” Pharmacology & Therapeutics, 1999, 83, 67-123.
Farmer, B.T., et al., “Localizing the NADP+binding site on the MurB enzyme by NMR,” Nat. Struct. Mol. Biol., 1998, 3(12), 995-997.
Fink, B.K., et al., “Interleukin 6 promotes murine lupus in NZB/NZW F1mice,” J. Clin. Invest., 1994, 94, 585-591.
Grossman, R.M., et al., “Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes,” Prot. Natl. Acad. Sci., 1989, 86, 6367-5371.
Grzesiek, S., et al., “Improved 3D triple-resonance NMR techniques applied to a 31 kDa protein,” J. Biomol. NMR, 1992, 96, 432-440.
Grzesiek, S., et al., “Amino acid type determination in the sequential assignment procedure of uniformly13C/15N-enriched proteins,” J. Biomolecular NMR, 1993, 3, 185-204.
Hansen, M.B., et al., “Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors,” Eur. J. Immunol., 1995, 348-354.
Harris, R.J., “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture,” J. of Chromatography A, 1995, 705, 129-134.
Hellström, K.E., et al., “Antibodies for drug delivery,”Controlled Drug Delivery, 2ndEd., Robinson, et al. (Eds.), Chapter 15, 1987, 623-653.
Hirano, T., et al., “Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin,” Nature, 1986, 324, 73-76.
Holliger,

Affiliated with

Also associated with

Rating

Antibody molecules having specificity for human IL-6 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody molecules having specificity for human IL-6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody molecules having specificity for human IL-6 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4313790